Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 10/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696171 | 1.00 | POLB (0.48) | POLBCMA1CTSKCTSSXIAP | |
| SCHEMBL27485070 | 1.00 | POLB (0.48) | POLBCMA1CTSKCTSSXIAP | |
| SCHEMBL5696170 | 1.00 | POLB (0.48) | POLBCMA1CTSKCTSSXIAP | |
| SCHEMBL3605952 | 0.97 | POLB (0.46) | POLBCMA1CTSKCTSSXIAP | |
| SCHEMBL3598521 | 0.93 | CTSK (0.46) | POLBCMA1CTSKCTSSHDAC8 | |
| SCHEMBL5047656 | 0.91 | DPP4 (0.53) | POLBCMA1CTSKCTSSCTSL | |
| SCHEMBL5280818 | 0.90 | CMA1 (0.53) | POLBCMA1CTSKCTSSELANE | |
| SCHEMBL10404191 | 0.90 | CMA1 (0.53) | POLBCMA1CTSKCTSSELANE | |
| SCHEMBL10404192 | 0.90 | CMA1 (0.53) | POLBCMA1CTSKCTSSELANE | |
| SCHEMBL7330566 | 0.89 | KLK5 (0.49) | POLBCMA1CTSKCTSSXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | POLB 1623/4885CMA1 147/4885CTSK 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.